| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| | 8-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K |
| Revenues: |
| Hospital Division | 198.5 | | | | | | | |
| Population Health Management Division | 20.8 | | | | | | | |
| Customers One | | 1.9 | 0.2 | | | | | |
| Other | | 16.9 | 1.4 | | | | | |
| Total revenues | 219.3 | 18.8 | 1.6 | 1.4 | 1.4 | 0.0 | 0.0 | 0.3 |
| Revenue growth [+] | 1066.8% | 1085.0% | 16.1% | 0.0% | 5800.9% | | -100.0% | |
| Customers One | | 1085.0% | | | | | | |
| Cost of goods sold | 205.8 | 14.6 | 0.9 | 0.8 | 0.5 | 0.0 | 0.0 | -0.1 |
| Gross profit | 13.5 | 4.1 | 0.7 | 0.5 | 0.9 | 0.0 | 0.0 | 0.5 |
| Gross margin | 6.1% | 22.1% | 42.6% | 39.2% | 62.9% | -31.6% | | 139.8% |
| Selling, general and administrative [+] | 18.0 | 12.2 | 3.3 | 4.2 | 1.2 | 1.8 | 0.4 | 0.1 |
| Sales and marketing | | | | 0.6 | 0.2 | | | |
| General and administrative [+] | 18.0 | 12.2 | 3.3 | 3.7 | 0.9 | 1.8 | 0.4 | |
| General and administrative expenses | 18.0 | 12.2 | 3.3 | 3.7 | 0.9 | 1.8 | 0.4 | 1.0 |
| Research and development | | 0.3 | 0.6 | 0.8 | 0.5 | | | |
| Other operating expenses | -13.1 | 0.7 | -8.0 | 0.2 | | 3.9 | | |
| EBITDA [+] | 8.6 | -8.3 | 5.0 | -4.5 | -0.8 | -5.2 | -0.4 | |
| EBITDA growth | -203.0% | -267.6% | -210.5% | 435.4% | -83.8% | 1051.0% | -9.6% | -36.1% |
| EBITDA margin | 3.9% | -44.2% | 312.4% | -328.2% | -61.3% | -22264.9% | | -148.6% |
| Depreciation | 13.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | |
| EBITA | -4.6 | -8.3 | 4.9 | -4.6 | -0.8 | -5.2 | -0.4 | -0.5 |
| EBITA margin | -2.1% | -44.2% | 311.5% | -339.6% | -61.5% | -22269.9% | | -148.6% |
| Amortization of intangibles | | 0.7 | 0.1 | | | 0.5 | | |
| EBIT [+] | -4.6 | -9.0 | 4.8 | -4.6 | -0.8 | -5.7 | -0.4 | -0.5 |
| EBIT growth | -49.2% | -286.1% | -204.4% | 452.2% | -85.2% | 1169.1% | -9.5% | -30.5% |
| EBIT margin | -2.1% | -48.0% | 305.5% | -339.6% | -61.5% | -24574.5% | | -148.6% |
| Non-recurring items [+] | 402.0 | | 3.5 | 2.3 | | | | |
| Asset impairment | 398.1 | | 3.5 | 2.3 | | | | |
| Interest expense, net [+] | 12.5 | 5.2 | 0.0 | 0.1 | 0.1 | 0.4 | 0.0 | 0.0 |
| Interest expense | 12.5 | 5.2 | | 0.1 | 0.1 | 0.4 | 0.0 | 0.0 |
| Interest income | | 0.0 | 0.0 | 0.0 | 0.0 | | 0.0 | |
| Other income (expense), net [+] | -0.6 | -0.4 | -6.9 | -0.1 | | 0.1 | | 0.0 |
| Gain (loss) on sale of assets | | | 0.1 | | | | | |
| Gain (loss) on debt retirement | | | -0.2 | -0.1 | | -0.1 | | |
| Other | 0.6 | -5.6 | -6.9 | -0.2 | -0.1 | -0.3 | 0.0 | |
| Pre-tax income | -419.6 | -14.7 | -5.5 | -7.1 | -1.0 | -6.0 | -0.5 | -0.5 |
| Income taxes | 13.1 | 1.0 | 0.0 | 0.0 | 0.0 | -6.6 | 7.0 | -0.6 |
| Tax rate | | | 0.0% | 0.0% | 0.0% | 109.7% | | 115.4% |
| Minority interest | -8.0 | 0.0 | | | | | | |
| Earnings from continuing ops | -424.8 | -13.7 | -5.7 | -7.1 | -1.0 | -6.0 | -0.5 | 0.1 |
| Earnings from discontinued ops | | | | | | 6.6 | -7.0 | 0.6 |
| Net income | -424.8 | -13.7 | -5.7 | -7.1 | -1.0 | 0.6 | -7.4 | 0.1 |
| Net margin | -193.7% | -72.7% | -356.3% | -520.8% | -69.5% | 2512.6% | | 25.1% |
| |
| Basic EPS [+] | ($0.67) | ($0.37) | ($1.14) | ($1.96) | ($0.56) | ($0.07) | ($0.01) | $0.00 |
| Growth | 81.1% | -67.5% | -41.8% | 251.3% | 677.3% | 531.7% | -495.5% | -110.9% |
| Diluted EPS [+] | ($0.67) | ($0.37) | ($1.14) | ($1.96) | ($0.56) | ($0.07) | ($0.01) | $0.00 |
| Growth | 81.1% | -67.5% | -41.8% | 251.3% | 677.3% | 531.7% | -495.5% | -110.9% |
| |
| Shares outstanding (basic) [+] | 634.0 | 36.9 | 5.0 | 3.6 | 1.7 | 83.7 | 39.7 | 29.2 |
| Growth | 1616.1% | 645.4% | 36.5% | 113.2% | -98.0% | 110.8% | 36.1% | 12.4% |
| Shares outstanding (diluted) [+] | 634.0 | 36.9 | 5.0 | 3.6 | 1.7 | 83.7 | 39.7 | 29.2 |
| Growth | 1616.1% | 645.4% | 36.5% | 113.2% | -98.0% | 110.8% | 36.1% | 12.4% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |